2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
May 17th 2022
Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.
July 9th 2016
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.